[Ip-health] PhRMA's reaction to Columbia's decision to cut prices

Andrew S. Goldman andrew.goldman at keionline.org
Wed Sep 14 11:32:54 PDT 2016


The price decrease was only just finalized: a reduction by 45%.

http://www.rcnradio.com/economia/ministro-alejandro-gaviria-anuncia-venta-de-cafesalud/

Andy




--
Andrew S. Goldman
Counsel, Policy and Legal Affairs
Knowledge Ecology International
andrew.goldman at keionline.org // www.twitter.com/ASG_KEI
tel.: +1.202.332.2670
www.keionline.org

On Wed, Sep 14, 2016 at 2:08 PM, Baker, Brook <b.baker at northeastern.edu>
wrote:

> Not at all deterred by the critique in the UN Secretary-General's High
> Level Panel on Medicines final report about industry and government
> pressure on Columbia to threaten the issuance of a compulsory license,
> PhRMA today issued a verbal pout against Columbia lesser decision to
> require a price drop on Novartis's extortionately priced anti-cancer
> medicine, Gleevec:  http://phrma.org/press-release/phrma-response-to-
> colombias-decision-to-enforce-a-declaration-of-public-interest
>
> Brook
> Professor Brook K. Baker
> Northeastern University School of Law
> 416 Huntington Ave.
> Boston, MA 02115
> (w) 617-373-3217
> (c) 617-259-0760
> (f) 617-373-5056
> b.baker at neu.edu
> Skype:  brook_baker
>
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>



More information about the Ip-health mailing list